Lower Risk Myelodysplastic Syndromes (MDS) Market - 2023-2031
Description
Lower Risk Myelodysplastic Syndromes (MDS) Market Overview:
The Lower Risk Myelodysplastic Syndromes (MDS) Market was valued at US$ 3,362.85 million in 2023 and is anticipated to reach US$ 7,052.79 million by 2031, at a CAGR of 0.097 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Lower Risk Myelodysplastic Syndromes (MDS) Market.
This report delivers a comprehensive overview of the Lower Risk Myelodysplastic Syndromes (MDS) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lower Risk Myelodysplastic Syndromes (MDS) Market. The Lower Risk Myelodysplastic Syndromes (MDS) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Lower Risk Myelodysplastic Syndromes (MDS) Market Scope:
By Type
• Erythropoiesis-Stimulating Agents (ESAs)
• Red Blood Cell Transfusion
• Erythroid Maturation Agents
• Demethylating Agents
• Immunosuppressive Agents
• Immunomodulatory Agents (Lenalidomide)
• Telomerase Inhibitors
• Others
By Route of Administration
• Oral
• Parenteral
By Age Group
• Adults
• Geriatrics
By Distribution Channel
• Hospital pharmacies
• Specialty Pharmacies
Key Players
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Sanofi-Aventis U.S. LLC.
• AbbVie Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd
• Geron.
• Keros Therapeutics
Major Highlights
This report delivers a comprehensive overview of the Lower Risk Myelodysplastic Syndromes (MDS) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lower Risk Myelodysplastic Syndromes (MDS) Market. The Lower Risk Myelodysplastic Syndromes (MDS) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
The Lower Risk Myelodysplastic Syndromes (MDS) Market was valued at US$ 3,362.85 million in 2023 and is anticipated to reach US$ 7,052.79 million by 2031, at a CAGR of 0.097 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Lower Risk Myelodysplastic Syndromes (MDS) Market.
This report delivers a comprehensive overview of the Lower Risk Myelodysplastic Syndromes (MDS) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lower Risk Myelodysplastic Syndromes (MDS) Market. The Lower Risk Myelodysplastic Syndromes (MDS) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
Lower Risk Myelodysplastic Syndromes (MDS) Market Scope:
By Type
• Erythropoiesis-Stimulating Agents (ESAs)
• Red Blood Cell Transfusion
• Erythroid Maturation Agents
• Demethylating Agents
• Immunosuppressive Agents
• Immunomodulatory Agents (Lenalidomide)
• Telomerase Inhibitors
• Others
By Route of Administration
• Oral
• Parenteral
By Age Group
• Adults
• Geriatrics
By Distribution Channel
• Hospital pharmacies
• Specialty Pharmacies
Key Players
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Sanofi-Aventis U.S. LLC.
• AbbVie Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd
• Geron.
• Keros Therapeutics
Major Highlights
This report delivers a comprehensive overview of the Lower Risk Myelodysplastic Syndromes (MDS) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lower Risk Myelodysplastic Syndromes (MDS) Market. The Lower Risk Myelodysplastic Syndromes (MDS) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
217 Pages
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Treatment Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Age Group
- 3.4. Snippet by Distribution Channel
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising product development activities and approval of novel therapies
- 4.1.1.2. Rising prevalence of low-risk myelodysplastic syndromes
- 4.1.2. Restraints
- 4.1.2.1. High cost of treatment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Unmet Needs
- 5.6. PESTEL Analysis
- 5.7. Patent Analysis
- 5.8. SWOT Analysis
- 6. By Type
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 6.1.2. Market Attractiveness Index, By Treatment Type
- 6.2. Erythropoiesis-Stimulating Agents (ESAs)*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Epoetin Alfa
- 6.2.4. Darbepoetin Alfa
- 6.3. Red Blood Cell Transfusion
- 6.4. Erythroid Maturation Agents
- 6.5. Demethylating Agents
- 6.5.1. Azacitidine
- 6.5.2. Decitabine
- 6.6. Immunosuppressive Agents
- 6.6.1. Antithymocyte Globulin
- 6.6.2. Cyclosporine
- 6.6.3. Others
- 6.7. Immunomodulatory Agents (Lenalidomide)
- 6.8. Telomerase Inhibitors
- 6.9. Others
- 7. By Route of Administration
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Oral*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Parenteral
- 7.3.1. Subcutaneous
- 7.3.2. Intravenous
- 7.3.3. Others
- 8. By Age Group
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 8.1.2. Market Attractiveness Index, By Age Group
- 8.2. Adults*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Geriatrics
- 9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Specialty Pharmacies
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.7.1. The U.S.
- 10.2.7.2. Canada
- 10.2.7.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.2. Germany
- 10.3.6.3. UK
- 10.3.6.4. France
- 10.3.6.5. Italy
- 10.3.6.6. Spain
- 10.3.6.7. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.2. Brazil
- 10.4.6.3. Argentina
- 10.4.6.4. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.2. China
- 10.5.6.3. India
- 10.5.6.4. Japan
- 10.5.6.5. South Korea
- 10.5.6.6. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 12. Company Profiles
- 12.1. Johnson & Johnson Services, Inc.*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Amgen Inc.
- 12.3. Bristol-Myers Squibb Company
- 12.4. Pfizer Inc.
- 12.5. Sanofi-Aventis U.S. LLC.
- 12.6. AbbVie Inc.
- 12.7. Novartis AG
- 12.8. Otsuka Pharmaceutical Co., Ltd
- 12.9. Geron.
- 12.10. Keros Therapeutics (*LIST NOT EXHAUSTIVE)
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
